PGNY Quote, Financials, Valuation and Earnings

The Cigna Group has a net margin of 4.43% compared to Progyny, Inc.'s net margin of 2.83%. Progyny, Inc.'s return on equity of 11.79% beat The Cigna Group's return on equity of 15.87%.

Progyny, Inc. has a consensus price target of $29.40, signalling upside risk potential of 14.49%. On the other hand The Cigna Group has an analysts' consensus of $324.92 which suggests that it could grow by 18.05%. Given that The Cigna Group has higher upside potential than Progyny, Inc., analysts believe The Cigna Group is more attractive than Progyny, Inc..

Progyny, Inc. has a beta of 0.932, which suggesting that the stock is 6.785% less volatile than S&P 500. In comparison The Cigna Group has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.71%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 2.2% to investors and pays a quarterly dividend of $1.51 per share. Progyny, Inc. pays -- of its earnings as a dividend. The Cigna Group pays out 46.19% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Progyny, Inc. quarterly revenues are $313.3M, which are smaller than The Cigna Group quarterly revenues of $69.8B. Progyny, Inc.'s net income of $13.9M is lower than The Cigna Group's net income of $2B. Notably, Progyny, Inc.'s price-to-earnings ratio is 40.66x while The Cigna Group's PE ratio is 12.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.81x versus 0.28x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

Clover Health Investments Corp. has a net margin of 4.43% compared to Progyny, Inc.'s net margin of -4.91%. Progyny, Inc.'s return on equity of 11.79% beat Clover Health Investments Corp.'s return on equity of -16.93%.

Progyny, Inc. has a consensus price target of $29.40, signalling upside risk potential of 14.49%. On the other hand Clover Health Investments Corp. has an analysts' consensus of $3.23 which suggests that it could grow by 37.59%. Given that Clover Health Investments Corp. has higher upside potential than Progyny, Inc., analysts believe Clover Health Investments Corp. is more attractive than Progyny, Inc..

Progyny, Inc. has a beta of 0.932, which suggesting that the stock is 6.785% less volatile than S&P 500. In comparison Clover Health Investments Corp. has a beta of 2.120, suggesting its more volatile than the S&P 500 by 111.968%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Clover Health Investments Corp. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $313.3M, which are smaller than Clover Health Investments Corp. quarterly revenues of $496.7M. Progyny, Inc.'s net income of $13.9M is higher than Clover Health Investments Corp.'s net income of -$24.4M. Notably, Progyny, Inc.'s price-to-earnings ratio is 40.66x while Clover Health Investments Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.81x versus 0.67x for Clover Health Investments Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health, Inc. has a net margin of 4.43% compared to Progyny, Inc.'s net margin of -4.6%. Progyny, Inc.'s return on equity of 11.79% beat Oscar Health, Inc.'s return on equity of -21.36%.

Progyny, Inc. has a consensus price target of $29.40, signalling upside risk potential of 14.49%. On the other hand Oscar Health, Inc. has an analysts' consensus of $14.67 which suggests that it could grow by 2.07%. Given that Progyny, Inc. has higher upside potential than Oscar Health, Inc., analysts believe Progyny, Inc. is more attractive than Oscar Health, Inc..

Progyny, Inc. has a beta of 0.932, which suggesting that the stock is 6.785% less volatile than S&P 500. In comparison Oscar Health, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Oscar Health, Inc. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $313.3M, which are smaller than Oscar Health, Inc. quarterly revenues of $3B. Progyny, Inc.'s net income of $13.9M is higher than Oscar Health, Inc.'s net income of -$137.5M. Notably, Progyny, Inc.'s price-to-earnings ratio is 40.66x while Oscar Health, Inc.'s PE ratio is 51.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.81x versus 0.34x for Oscar Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.